A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Neoplasms
- Prostatic Neoplasms
- Endometrial Neoplasms
- Colorectal Neoplasms
- Solid Carcinoma
- Pancreatic Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
- Last updated on ClinicalTrials.gov
- August 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Francisco Cancer Center · San Francisco, CA
North Carolina · 1
- Carolina BioOncology Institute, LLC · Huntersville, NC
Oklahoma · 1
- University of Oklahoma Health Sciences Center · Oklahoma City, OK
Texas · 1
- The University of Texas, MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.